Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The human epidermal growth factor receptor 2 (HER2) plays an essential role in the tumorigenesis and tumor progression in cancer.
|
31829777 |
2020 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
To investigate the role of α3β1 in HER2-driven tumorigenesis in vivo, we generated a HER2-driven MMTV-cNeu mouse model of mammary tumorigenesis with targeted deletion of Itga3 (Itga3 KO mice).
|
31101121 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These results reveal the hitherto unknown c-Src/mTORC1/PRC2 axis, which is essential for ErbB2-driven carcinogenesis.
|
31263101 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Correction: Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
|
30375491 |
2019 |
Carcinogenesis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The human epidermal growth factor receptor 2 (ERBB2) may harbour somatic mutations that drive breast tumorigenesis.
|
30456437 |
2019 |
Carcinogenesis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The ErbB1 and ErbB2 mRNA and protein expression levels in the SNIP group were positively correlated with the SNIP dysplasia grade.<b>Conclusion:</b> Upregulation of ErbB1 and ErbB2 expression may be associated with SNIP pathogenesis and carcinogenesis.
|
31556771 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Altogether, these data indicate that the inhibition of HER2-induced tumorigenesis by miR-489 overexpression was due to altering progenitor cell populations while decreasing tumor growth and metastasis via influencing tumor promoting genes DEK and SHP2.
|
30104710 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In addition, we used a pre-clinical xenograft HER2 mouse model (NOD/SCID mice) for in vivo tumorigenesis assessment.
|
31450192 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These findings demonstrate a novel mechanism of HER2-driven carcinogenesis and suggest the applicability of combined HER2 and HDAC targeting in breast cancer therapy.
|
31111958 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
(1) Background: Human epidermal growth factor receptor 2 (HER2)/neu-driven carcinogenesis is delayed by preventive vaccines able to elicit autochthonous antibodies against HER2/neu.
|
30979001 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu-Driven Tumorigenesis.
|
30602621 |
2019 |
Carcinogenesis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Human epidermal growth factor 2 (HER2) gene overexpression in breast carcinoma cell lines has been shown to drive mammary carcinogenesis and tumor growth and invasion through its effects on mammary stem cells.
|
31550723 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Here, we show that the Src homology phosphotyrosyl phosphatase 2 (Shp2) encoded by the Ptpn11 gene is a requisite for ErbB2-induced tumorigenesis.
|
30467378 |
2019 |
Carcinogenesis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
<i>HER2</i> amplification is a well-known driver of oncogenesis in breast cancer, with associated increased risk of brain metastases and response to HER2-directed therapy.
|
30373904 |
2019 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
During a research program carried on 113 cases of female breast cancer, immunohistochemically categorized in Her2-positive (29 cases), Her2-negative (57 cases) and triple negative (27 cases), aimed to evaluate the role of environmental particulate in carcinogenesis by elemental microanalysis, for the first time in literature we have detected a REM uptake, in detail europium (Eu), dysprosium (Dy) and praseodymium (Pr), inside the neoplastic cells belonging to a single triple negative breast cancer.
|
28185164 |
2018 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
HER-2/Epstein-Barr virus crosstalk in human gastric carcinogenesis: A novel concept of oncogene/oncovirus interaction.
|
28562165 |
2018 |
Carcinogenesis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Our comprehensive assessment of <i>ERBB2</i> mutations offers a fundamental database to help customize therapy for ERBB2-driven cancers.We identified several <i>ERBB2</i> mutations as activating mutations related to tumorigenesis.
|
29967253 |
2018 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Receptor tyrosine kinases (RTK), such as ErbB2, bind the ShcA PTB domain to promote breast tumorigenesis by engaging Grb2 downstream of the ShcA tyrosine phosphorylation sites to activate AKT/mTOR signaling.
|
29453318 |
2018 |
Carcinogenesis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, EphA6 may serve an important role in breast carcinogenesis and may pose as a novel prognostic indicator and therapeutic target for breast cancer, particularly in patients with steroid receptor negative expression and HER-2 overexpression.
|
29552165 |
2018 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, OX40 triggering can either impair or ameliorate immunoprevention of HER2/neu-driven mammary carcinogenesis depending on the schedule of aOX40 administration.
|
30221061 |
2018 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Taken together, these findings indicate that the HER2-mediated inhibition of Beclin 1 and autophagy likely contributes to HER2-mediated tumorigenesis and that strategies to block HER2/Beclin 1 binding and/or increase autophagy may represent a new therapeutic approach for HER2-positive breast cancers.
|
29610308 |
2018 |
Carcinogenesis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The transcriptional regulation of the human epidermal growth factor receptor-2 (HER2) contributes to an enhanced HER2 expression in HER2-positive breast cancers with HER2 gene amplification and HER2-low or HER2-negative breast cancers following radiotherapy or endocrine therapy, and this drives tumorigenesis and the resistance to therapy.
|
29035388 |
2018 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Hyperinsulinemia-induced IGF1R and HER2 up-regulation could also increase the possibility of forming of IGF1R/HER2 heterodimers to support cell growth/proliferation/progression in esophageal carcinogenesis.
|
29662006 |
2018 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
DMBA promotes ErbB2‑mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability.
|
30015966 |
2018 |
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Current evidence suggests that HER2-driven tumorigenesis requires HER3.
|
29760043 |
2018 |